Sectors
ARTV
Artiva Biotherapeutics, Inc.
11.14
1 x 11.12
8 x 11.32
bid
ask
-
0.08
0.71%
09:40 AM
timesize
| Ytd | 159.67% | |
| 1y | 335.16% |
11.14
day range
11.28
2.22
52 week range
14.53
| Open | 11.18 | Prev Close | 11.22 | Low | 11.14 | High | 11.28 | Mkt Cap | 277.90M |
| Vol | 5.22K | Avg Vol | 529.98K | EPS | -3.54 | P/E | -3.18 | Forward P/E | -3.18 |
| Beta | 2.16 | Short Ratio | 20.47 | Inst. Own | 89.07% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 9.36 | 200-d Avg | 6.70 | 1yr Est | 21.25 |
| Income Statement | |||
| Operating Expenses | 26.89M | ||
| Research and Development Expense | 21.93M | ||
| Selling, General and Administrative Expense | 4.97M | ||
| Operating Income | -26.89M | ||
| Net Income | -25.00M | ||
| Net Income Common Stock | -25.00M | ||
| Net Income Common Stock (USD) | -25.00M | ||
| Consolidated Income | -25.00M | ||
| Earnings per Basic Share | -0.63 | ||
| Earnings per Basic Share (USD) | -0.63 | ||
| Earnings per Diluted Share | -0.63 | ||
| Earning Before Interest & Taxes (EBIT) | -25.00M | ||
| Earning Before Interest & Taxes (USD) | -25.00M | ||
| Weighted Average Shares | 39.41M | ||
| Weighted Average Shares Diluted | 39.41M | ||
| Balance Sheet | |||
| Cash and Equivalents | 301.92M | ||
| Cash and Equivalents (USD) | 301.92M | ||
| Investments | 47.94M | ||
| Investments Current | 47.94M | ||
| Current Assets | 352.28M | ||
| Property, Plant & Equipment Net | 15.09M | ||
| Total Assets | 368.63M | ||
| Debt Current | 3.30M | ||
| Total Debt | 9.85M | ||
| Current Liabilities | 14.58M | ||
| Debt Non-Current | 6.55M | ||
| Total Liabilities | 21.13M | ||
| Accumulated Retained Earnings (Deficit) | -379.07M | ||
| Accumulated Other Comprehensive Income | -21.00K | ||
| Shareholders Equity | 347.50M | ||
| Shareholders Equity (USD) | 347.50M | ||
| Assets Non-Current | 16.36M | ||
| Total Debt (USD) | 9.85M | ||
| Liabilities Non-Current | 6.55M | ||
| Trade and Non-Trade Payables | 1.39M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 692.00K | ||
| Net Cash Flow from Financing | 283.27M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 280.50M | ||
| Capital Expenditure | -415.00K | ||
| Issuance (Purchase) of Equity Shares | 283.27M | ||
| Issuance (Repayment) of Debt Securities | -12.00K | ||
| Net Cash Flow from Investing | 17.59M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 18.00M | ||
| Net Cash Flow from Operations | -20.35M | ||
| Share Based Compensation | 1.87M | ||